Overview

A Phase II Clinical Trial Evaluating Ipilimumab, Nivolumab, and Cabozantinib in Patients With Anti-PD-1(L1) Refractory Cutaneous Melanoma

Status:
Not yet recruiting

Trial end date:
2031-03-01

Target enrollment:

Participant gender:

Summary

The primary objective of this clinical trial is to evaluate the clinical efficacy and progression free survival of the triplet combination of ipilimumab + nivolumab + cabozantinib in patients with anti-PD-1/PD-L1 refractory metastatic cutaneous melanoma.

Phase:

Phase 2

Details

Lead Sponsor:

Providence Health & Services

Collaborators:

Providence Cancer Center
Providence Cancer Center, Earle A. Chiles Research Institute

Treatments:

Ipilimumab
Nivolumab